KYV-101 (Biological) - 1 ×10^8 cells 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 KYV-101 (KYV-101, Biological, KYV-101 (Biological) - 1 ×10^8 cells) Kyverna Therapeutics·Progressive Multiple Sclerosis 133 trials

Overview Program	KYV-101 (Biological) - 1 ×10^8 cells
Overview Company	Kyverna Therapeutics
Overview Modality	CGT
Overview Target	Progressive Multiple Sclerosis
Overview Indication	Progressive Multiple Sclerosis
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Editorial scope · structured catalog
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

MoA Mechanism	involves modulation of the Notch1 signaling pathway
MoA Biomarker	EGFR inhibition was down-regulation of MGMT expression

Clinical Program phase	PHASE_1
Clinical Trial activity	No active/completed counts

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 KYV-101 (KYV-101, Biological, KYV-101 (Biological) - 1 ×10^8 cells) Kyverna Therapeutics·Progressive Multiple Sclerosis 133 trials

Overview Program	KYV-101 (Biological) - 1 ×10^8 cells
Overview Company	Kyverna Therapeutics
Overview Modality	CGT
Overview Target	Progressive Multiple Sclerosis
Overview Indication	Progressive Multiple Sclerosis
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Editorial scope · structured catalog
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

MoA Mechanism	involves modulation of the Notch1 signaling pathway
MoA Biomarker	EGFR inhibition was down-regulation of MGMT expression

Clinical Program phase	PHASE_1
Clinical Trial activity	No active/completed counts